Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-9pm4c Total loading time: 0 Render date: 2024-04-25T11:30:38.034Z Has data issue: false hasContentIssue false

Chapter 5 - Neuroleptic parkinsonism

Published online by Cambridge University Press:  05 July 2015

By
Joseph H. Friedman
Edited by
Joseph H. Friedman
Joseph H. Friedman
Affiliation:
Department of Neurology, Brown University
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Medication-Induced Movement Disorders , pp. 53 - 60
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Marsden, CD, Mindham, RHS, Mackay, AVP. Extrapyramidal movement disorders produced by antipsychotic drugs. In: Bradley, PB, Hirsch, SR, eds. The Psychopharmacology and Treatment of Schizophrenia. Oxford: Oxford University Press, 1986:340–402.Google Scholar
Easterford, K, Clough, P, Kellett, M, et al. Reversible parkinsonism with normal beta CIT in patients exposed to sodium valproate. Neurol 2004;62:1435–7.Google ScholarPubMed
Lang, AE. Lithium and parkinsonism. Ann Neurol 1984;15:214.CrossRefGoogle ScholarPubMed
Stephen, PJ, Wilson J. Drug-induced parkinsonism in the elderly. Lancet 1984;2:1082–3.Google Scholar
Friedman, JH. Parkinson’s disease psychosis: Update. Behav Neurol 2013;27:469–77.CrossRefGoogle ScholarPubMed
Meltzer, HY, Massey, BW. The role of serotonin receptors in the action of atypical antipsycotic drugs. Curr Opin Pharmacol 2011;11:59–67.CrossRefGoogle Scholar
Kapur, S, Seeman, P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implication for atypical antipsychotic action. J Psychiatry Neurosci 2000;25:161–6.Google ScholarPubMed
Donlon, PT, Stenson, RL. Neuroleptic-induced extrapyramidal symptoms. Dis Nerv System 1976; 7: 629–35.Google Scholar
Gerlach, J, Rasmussen, T, Hansen, L, Kristjansen, P. Antiparkinson agents and long-term neuroleptic treatment. Acta Psychi Neurol 1977;55:251–60.Google ScholarPubMed
Klawans, HL, Bergen, D, Bruyn, GW. Prolonged drug-induced parkinsonism. Confinia Neurologica 1973;35:368–77.Google ScholarPubMed
Negrotti, A, Calzetti, S. A Long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism. Mov Disord 1997;12:107–10.CrossRefGoogle ScholarPubMed
Hardie, RJ, Lees, AJ. Neuroleptic-induced Parkinson’s syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 1988;51:850–4.CrossRefGoogle ScholarPubMed
Caroff, SN, Hurford, I, Lybrand, J, Campbell, EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE Schizophrenia Trial. Psychiatry for the Neurologist 2011;29:127–148.Google ScholarPubMed
Halliday, J, Farrington, S, MacDonald, S, et al. Nithsdale Schizophrenia Surveys 23: movement disorders. 20-year review. B J Psychiatry 2002;181;5:422–7.CrossRefGoogle ScholarPubMed
Peluso, MJ, Lewis, SW, Barnes, TRE, Jonas, PB. Extrapyramidal motor side effects of first and second generation antipsychotic drugs. Br J Psychiatry 2012;200:387–92.CrossRefGoogle ScholarPubMed
Haddad, MP, Das, A, Keyhanis, S, Chaudhry, IB. Antipsychotic drugs and extrapyramidal side effect in first episode psychosis: a systematic review. J Psychopharmacology 2012;26(5Suppl):15–26.CrossRefGoogle ScholarPubMed
Rosebush, PI, Mazurek, MF. Neurologic side effects in neuroleptic naïve patients treated with haloperidol or risperidone. Neurol 1999;52:782–5.Google ScholarPubMed
Ayd, FJ. A Survey of drug-induced extrapyramidal reactions. JAMA 1961;175:102–8.CrossRefGoogle ScholarPubMed
Tinazzi, M, Morgante, F, Matinella, A, et al. Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: A 2-year follow-up multicenter study. Schizophr Res 2014;152:233–349.CrossRefGoogle ScholarPubMed
The National institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. Phenothiazine treatment in acute schizophrenia. Effectiveness. Arch Gen Psychiatry 1964;10:246–61.Google Scholar
Hausner, RS. Neuroleptic-induced parkinsonism and Parkinson’s disease: differential diagnosis and treatment. J Clin Psychiatry 1993;44:13–16.Google Scholar
Sethi, K, Zamrini, EY. Asymmetry in clinical features of drug-induced parkinsonism. J Neuropsych 1990;2:54–6.Google ScholarPubMed
Hughes, AJ, Daniel, SE, Kilford, L, Lees, AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–4.CrossRefGoogle ScholarPubMed
Simpson, GM, Angus, JW. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scand Suppl 1970;212:11–19.CrossRefGoogle ScholarPubMed
Lou, JS, Kearns, G, Benice, T, et al. Levodopa improves physical fatigue in Parkinson’s disease: a double blind, placebo controlled crossover study. Mov Disord 2003;18:1108–14.CrossRefGoogle ScholarPubMed
Gershanik, O. Drug-Induced Parkinsonism in the aged. Recognition and prevention. Drugs and Aging 1994;5:127–32.CrossRefGoogle ScholarPubMed
McCreadie, RG, Robertson, LF, Wiles, DH. The Nithsdale schizophrenia surveys IX: akathisia, parkinsonism, tardive dyskinesia and plasma neuroleptic levels. B J Psychi 1992;160:793–9.CrossRefGoogle ScholarPubMed
Van Harten, PN, Matroos, GE, Hoek, HW, et al. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia. The Curacao extrapyramidal syndromes study I. Schiz Res 1996;19:195–203.CrossRefGoogle ScholarPubMed
Modestin, J, Stephan, PL, Erni, T, et al. Prevalence of extrapyramidal syndromes in psychiatric inpatients and relation of clozapine treatment to tardive dyskinesia. Schiz Res 2000;42:223–30.CrossRefGoogle Scholar
Muscettola, G, Barbato, G, Pampallona, S, et al. Extrapyramidal syndromes in neuroleptic-treated patients: Prevalence, risk factors, and association with tardive dyskinesia. J Clin Psychopharmacol 1999;19:203–8.CrossRefGoogle ScholarPubMed
Hill, AL, Sun, B, McDonnel, DP. Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine. Clin Schizophrenia and Related Psychoses. 2014;7:216–22.CrossRefGoogle ScholarPubMed
Seijo-Martinez, M, Castro Del Rio, M, Rodriguez Alvarez, J, et al. Prevalence of parkinsonism and Parkinson’s disease in the Arosa Island (Spain): a community-based door-to-door survey. J Neurol Sci 2011;304:49–54.CrossRefGoogle Scholar
Kasten, M, Bruggemann, M, Konig, IR, et al. Risk for antipsychotic extrapyramidal symptoms: influence of family history and genetic susceptibility. Psychoparmalogy (Berl) 2011;214:729–36.Google ScholarPubMed
Freyhan, FA. Therapeutic implications of differential effects of new phenothiazine compounds. Am J Psychiatry 1959;115:577–85.CrossRefGoogle ScholarPubMed
Medina, C, Kramer, MD, Kurland, AA. Biperiden in the treatment of phenothiazine-induced extra-pyramidal reactions. JAMA 1962;182:1127–8.CrossRefGoogle Scholar
Azima, H, Ogle, W, Effects of largactil in mental syndromes. Can Med Assoc J. 1954;71:116–21.Google ScholarPubMed
Marsden, CD, Jenner, P. The pathophysiology of extrapyramidal side effects of neuroleptic drugs. Psychol Med 1980;10:55–72.CrossRefGoogle ScholarPubMed
Kennedy, PF, Hershon, HI. McGuire, RJ. Extrapyramidal disorders after prolonged phenothiazine therapy. Br J Psychiatry 1971;118:509–18.CrossRefGoogle ScholarPubMed
Fernandez, HH, Krupp, B, Friedman, JH. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: a 14-year follow-up. Neurology 2001;56:805–7.CrossRefGoogle ScholarPubMed
Tenback, DE, van Harten, PN. Epidemiology and risk factors for (tardive) dyskinesia. Int Rev Neurobiol 2011;98:211–30.CrossRefGoogle ScholarPubMed
Foubert-Samier, A, Helmer, C, et al. Past exposure to neuroleptic drugs and risk of Parkinson’s disease in an elderly cohort. Neurol 2012;79:1615–21.Google Scholar
Mindham, RHS. Assessment of drug-induced extrapyramidal reactions and of drugs given for their control. Br J Clin Pharmac 1976; Suppl, 395–400.CrossRefGoogle Scholar
Magnus, RV. A comparison of biperiden hydrochloride and benzhexol in the treatment of drug-induced parkinsonism. J Int Med Res 1980;8:343–6.CrossRefGoogle ScholarPubMed
Silver, H, Geraisy, N, Schwartz, M. No differenece in the effect of biperiden and amantadine on parkinsonism and tardive dyskinesia type involuntary movements. A double blind crossover, placebo controlled study in medicated chronic schizophrenic patients. J Clin Psychiatry 1995;56:167–70.Google Scholar
Zemishlany, Z, Aizenberg, D, Weiner, D, Weizman, A. Thrihexiphenidyl abuse in schizophrenic patients. Int Clin Psychopharmacol 1996;11:199–202.CrossRefGoogle ScholarPubMed
Greenblatt, DJ, Dimascio, A, Harmatz, JS, et al. Pharmacokinetics and clinical effects of amantadine in drug-induced extrapyramidal symptoms. J Clin Pharmacol 1977;17:704–8.CrossRefGoogle ScholarPubMed
McGeer, PL, Boulding, JE, Gibson, WC, Foulkes, RG. Drug-induced extrapyramidal reactions: treatment with diphenhydramine hydrochloride and dihydroxyphenlalanine. JAMA 1961;177:666–70.CrossRefGoogle Scholar
Fleming, P, Makar, H, Hunter, KR. Levodopa in drug-induced extrapyramidal disorders. Lancet 1970;ii:11286.Google Scholar
Kimura, N, Tsukue, I. L-dopa therapy in drug-induced parkinsonism evaluated by the method of measuring the facial expression. Hiroshima J Med Sci 1971;20:55–63.Google ScholarPubMed
Friedman, JH. Managing Parkinson’s disease in patients with schizophrenic disorders. Park Related Disord 2011;17:198–200.CrossRefGoogle ScholarPubMed
Sadananda, SK, Holla, B, Viswanath, B, et al. Effectiveness of electroconvulsive therapy for drug-induced parkinsonism in the elderly. J ECT 2013;29:e6–7.CrossRefGoogle ScholarPubMed
Friedman, JH, Koller, WC, Lannon, MD, et al. Benztropine versus clozapine for the treatment of tremor in Parkinson’s disease. Neurol 1997;48:1077–81.Google ScholarPubMed
Friedman, JH, Lannon, MC. Clozapine responsive tremor in Parkinson’s disease. Mov Disord 1990;5:225–9.CrossRefGoogle ScholarPubMed
Pringsheim, T, Doja, A, Belanger, S, et al. Treatment recommendations for extrapyramidal side effects associated with second generation antipsychotics in children and adolescents. Paed Child Health 2011;16:590–8.CrossRefGoogle Scholar
Friedman, JH, Fernandez, HH, Trieschmann, MM. Parkinsonism in a nursing home: underrecognition. J Ger Psychiatry Neurol 2004;17:39–41.CrossRefGoogle Scholar
Friedman, JH, Skeete, R, Fernandez, HH. Unrecognized parkinsonism in acute care medical patients receiving neurological consultations. J Geront A Biol Sci Med Sci 2003;58:94–5.CrossRefGoogle ScholarPubMed
Pitcairn, TK, Clemie, S, Gray, JM, Pentland, B. Non-verbal cues in the self-presentation of Parkinson patients. Br J Clin Psychiatry 1990;29(Pt2):177–84.CrossRefGoogle Scholar
Tickle-Degnan, L, Lyons, KD. Practitioners’ impressions of patients with Parkinson’s disease: the social ecology of the expressive mask. Soc Sci 2004;58:603–14.Google Scholar
Tickle-Degnan, L, Zebrowitz, LA, Ha, HI. Culture, gender and health care stigma: Practitioners’ response to facial masking experienced by people with Parkinson’s disease. Soc Sci Med 2011;73:95–102.CrossRefGoogle Scholar
Hermanns, M. The invisible and visible stigmatization of Parkinson’s disease. J Am Assoc Nurse Pract 2013;25:563–6.Google ScholarPubMed
Olivares Romero, J, Arjona Padilla, A. Diagnostic accuracy of 123 FD-CIT SPECT in diagnosing drug-induced parkinsonism: a prospective study. Neurologia 2013;28:276–82.Google ScholarPubMed
Vlaar, AM, Bouwmans, A, Mess, WH, et al. Transcranial duplex in the differential diagnosis of parkinsonian syndromes: a systematic review. J Neurol 2009;256:530–8.CrossRefGoogle ScholarPubMed
Luo, WF, Zhang, YC, Sheng, YJ, et al. Transcranial sonography on Parkinson’s disease and essential tremor in a Chinese population. Neurol Sci 2012;33:1005–9.CrossRefGoogle ScholarPubMed
Chitsa, ZA, Mehrbad, N, Saadatnia, M, et al. Transcranial sonography on Parkinson’s disease and essential tremor. J Res Med Sci 2013;18(Suppl1):S28–31.Google Scholar
Berg, D, Behnke, S, Seppi, K, et al. Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson disease. Mov Disord 2013;28:216–9.CrossRefGoogle Scholar
Berg, D, Jabs, B, Merschdorf, U, et al. Echogenicity of sutbstantia determined by transcranial ultrasound correlates with severity of Parkinson symptoms induced by neuroleptic. Biol Psychiatry 2001;50:463–7.CrossRefGoogle Scholar
Kwon, DH, Kim, JM, Oh, SH, et al. Seven Tesla magnetic resonance images of the sunstantia nigra in Parkinson’s disease. Ann Neurol 2012;71:267–77.CrossRefGoogle Scholar
Iselin-Chaves, IA, Grotzsch, H, Besson, M, et al. Naloxone responsive acute dystonia and parkinsonism following general anesthesia. Anaesthesia 2009;64:1359–62.CrossRefGoogle Scholar
Perez-Lloret, S, Amaya, M, Merello, M. Pregabalin-induced parkinsonism: a case report. Clin Neuropharmacol 2009;32:353–4.CrossRefGoogle ScholarPubMed
Miletic, V, Relja, M. Citalopram-induced Parkinson syndrome: case report. Clin Neuropharmacol 2011;34:92–3.CrossRefGoogle ScholarPubMed
Draper, B, Berman, K. Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly. Drugs Aging 2008;25:501–19.CrossRefGoogle ScholarPubMed
Caley, C, Friedman, JH. Does fluoxetine exacerbate Parkinson’s disease? J Clin Psychiatry 1992;53:278–82.Google ScholarPubMed
Pae, CU. Use of antidepressants for depression in patients with Parkinson’s disease. Exp Opin Pharmacother 2013;14:255–7.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×